Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis.
Butyrivibrio
Gut microbiota
Infantile cholestasis (IC)
Microbiota-derived metabolites
Ruminococcus
Veillonella
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
18 11 2023
18 11 2023
Historique:
received:
26
01
2023
accepted:
06
11
2023
medline:
20
11
2023
pubmed:
19
11
2023
entrez:
19
11
2023
Statut:
epublish
Résumé
Infantile cholestasis (IC) is the most common hepatobiliary disease in infants, resulting in elevated direct bilirubin levels. Indeed, hepatointestinal circulation impacts bile acid and bilirubin metabolism. This study evaluates changes in the gut microbiota composition in children with IC and identifies abnormal metabolite profiles associated with microbial alterations. The gut microbiota in the IC group exhibits the higher abundance of Veillonella, Streptococcus and Clostridium spp. (P < 0.05), compared to healthy infants (CON) group. Moreover, the abundance of Ruminococcus, Vibrio butyricum, Eubacterium coprostanogenes group, Intestinibacter, and Faecalibacterium were lower (P < 0.05). In terms of microbiota-derived metabolites, the levels of fatty acids (palmitoleic, α-linolenic, arachidonic, and linoleic) (P < 0.05) increased and the levels of amino acids decreased in IC group. Furthermore, the abundances of Ruminococcus, Eubacterium coprostanoligenes group, Intestinibacter and Butyrivibrio are positively correlated with proline, asparagine and aspartic acid, but negatively correlated with the α-linolenic acid, linoleic acid, palmitoleic acid and arachidonic acid. For analysis of the relationship between the microbiota and clinical index, it was found that the abundance of Veillonella and Streptococcus was positively correlated with serum bile acid content (P < 0.05), while APTT, PT and INR were negatively correlated with Faecalibalum and Ruminococcus (P < 0.05). Microbiota dysbiosis happened in IC children, which also can lead to the abnormal metabolism, thus obstructing the absorption of enteral nutrition and aggravating liver cell damage. Veillonella, Ruminococcus and Butyrivibrio may be important microbiome related with IC and need further research.
Sections du résumé
BACKGROUND
Infantile cholestasis (IC) is the most common hepatobiliary disease in infants, resulting in elevated direct bilirubin levels. Indeed, hepatointestinal circulation impacts bile acid and bilirubin metabolism. This study evaluates changes in the gut microbiota composition in children with IC and identifies abnormal metabolite profiles associated with microbial alterations.
RESULTS
The gut microbiota in the IC group exhibits the higher abundance of Veillonella, Streptococcus and Clostridium spp. (P < 0.05), compared to healthy infants (CON) group. Moreover, the abundance of Ruminococcus, Vibrio butyricum, Eubacterium coprostanogenes group, Intestinibacter, and Faecalibacterium were lower (P < 0.05). In terms of microbiota-derived metabolites, the levels of fatty acids (palmitoleic, α-linolenic, arachidonic, and linoleic) (P < 0.05) increased and the levels of amino acids decreased in IC group. Furthermore, the abundances of Ruminococcus, Eubacterium coprostanoligenes group, Intestinibacter and Butyrivibrio are positively correlated with proline, asparagine and aspartic acid, but negatively correlated with the α-linolenic acid, linoleic acid, palmitoleic acid and arachidonic acid. For analysis of the relationship between the microbiota and clinical index, it was found that the abundance of Veillonella and Streptococcus was positively correlated with serum bile acid content (P < 0.05), while APTT, PT and INR were negatively correlated with Faecalibalum and Ruminococcus (P < 0.05).
CONCLUSION
Microbiota dysbiosis happened in IC children, which also can lead to the abnormal metabolism, thus obstructing the absorption of enteral nutrition and aggravating liver cell damage. Veillonella, Ruminococcus and Butyrivibrio may be important microbiome related with IC and need further research.
Identifiants
pubmed: 37980506
doi: 10.1186/s12866-023-03115-1
pii: 10.1186/s12866-023-03115-1
pmc: PMC10656868
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Bile Acids and Salts
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
357Informations de copyright
© 2023. The Author(s).
Références
Zhonghua Gan Zang Bing Za Zhi. 2019 May 20;27(5):325-329
pubmed: 31177655
Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):263-7
pubmed: 24746684
Ital J Pediatr. 2015 Oct 01;41:69
pubmed: 26428285
J Hepatol. 2013 May;58(5):949-55
pubmed: 23333527
Gut Microbes. 2020 Nov 9;12(1):1802866
pubmed: 32835590
Hepatology. 1997 May;25(5):1077-84
pubmed: 9141420
Liver Int. 2019 Jul;39(7):1186-1196
pubmed: 31125502
Aliment Pharmacol Ther. 2018 Jan;47(2):192-202
pubmed: 29083037
Front Microbiol. 2018 Nov 13;9:2682
pubmed: 30483228
Front Nutr. 2021 Jun 25;8:700058
pubmed: 34250000
Nutrients. 2022 Apr 09;14(8):
pubmed: 35458130
Hepatology. 2016 Jan;63(1):185-96
pubmed: 26044703
Sci Transl Med. 2016 Jun 15;8(343):343ra81
pubmed: 27306663
J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):154-168
pubmed: 27429428
mSystems. 2019 Dec 17;4(6):
pubmed: 31848302
Gastroenterology. 2011 Nov;141(5):1773-81
pubmed: 21839040
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Apr 30;40(4):595-600
pubmed: 32895142
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):346-360
pubmed: 30903105
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):440-452
pubmed: 29670252
Front Immunol. 2021 Sep 23;12:698900
pubmed: 34630385
Eur J Pediatr. 2011 Mar;170(3):279-84
pubmed: 21249394
Am J Physiol. 1997 Jun;272(6 Pt 1):G1587-93
pubmed: 9227497
Prostaglandins Leukot Essent Fatty Acids. 2020 Nov;162:102182
pubmed: 33038831
J Zhejiang Univ Sci B. 2015 Jun;16(6):436-46
pubmed: 26055905
Front Physiol. 2021 Oct 08;12:715852
pubmed: 34690796
J Anim Sci. 2020 Mar 1;98(3):
pubmed: 32141506
Front Nutr. 2022 May 19;9:890277
pubmed: 35669071
J Pediatr. 2016 Apr;171:171-7.e1-4
pubmed: 26858187
Pediatr Rev. 2004 Nov;25(11):388-96
pubmed: 15520084